Dr. Nastoupil on Navigating the Treatment Landscape of iNHL

Loretta J. Nastoupil, MD, associate professor, director, Lymphoma Outcomes Database, section chief, New Drug Development, Department of Lymphoma/Myeloma, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses navigating the treatment landscape of indolent non-Hodgkin lymphoma (iNHL).

The treatment landscape of iNHL is rapidly expanding and several novel therapies, including targeted options, have emerged for patients, Nastoupil says. However, navigating the growing armamentarium is an ongoing challenge in iNHL, especially considering that data from randomized studies, which may inform treatment selection, are limited, Nastoupil explains. When deciding on a treatment plan, patient-specific characteristics, as well as the efficacy and toxicity associated with the regimen, must be taken into consideration​, Nastoupil says. Moreover, these factors should be considered at every line of therapy because patientoutcomes can differ greatly, Nastoupil adds.

Moreover, in the last few years, the B-cell receptor signaling targeted agents became available to treat patients with iNHL, as did CAR T-cell therapies and bispecific antibodies, Nastoupil continues. With these newer treatment options, optimizing treatment selection is largely based on the patient’s prior treatments, past responses, risk of potential toxicities, and comorbidities, Nastoupil concludes.